This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions
by Zacks Equity Research
Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.
ALNYPositive Net Change PFEPositive Net Change ANIPNegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals vaccines
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
by Zacks Equity Research
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
VRTXPositive Net Change ANIPNegative Net Change FATEPositive Net Change EDITPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
by Zacks Equity Research
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
MRKPositive Net Change SMMTPositive Net Change TILNegative Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
NVSPositive Net Change INCYPositive Net Change EXELNegative Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
by Zacks Equity Research
Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.
VRTXPositive Net Change ANIPNegative Net Change EDITPositive Net Change
biotechs
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
by Zacks Equity Research
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
NVOPositive Net Change FOLDPositive Net Change ANIPNegative Net Change FATEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Acadia (ACAD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Acadia (ACAD) stock based on the movements in the options market lately.
ACADPositive Net Change
biotechnology biotechs medical
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
by Ahan Chakraborty
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
REGNPositive Net Change NVSPositive Net Change BIIBPositive Net Change PFEPositive Net Change NVOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
by Zacks Equity Research
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
NVSPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechs medical pharmaceuticals
Gilead, MRK Report Data From Investigational Combination Study for HIV
by Zacks Equity Research
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
GSKPositive Net Change ALNYPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs pharmaceuticals
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
by Zacks Equity Research
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
ALNYPositive Net Change NVOPositive Net Change FOLDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
by Zacks Equity Research
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change MDGLNegative Net Change
biotechs earnings medical pharmaceuticals
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
by Zacks Equity Research
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
ALNYPositive Net Change TEVAPositive Net Change FOLDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
by Zacks Equity Research
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
ALNYPositive Net Change CPRXPositive Net Change ANIPNegative Net Change AVDLPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
by Zacks Equity Research
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.
ALNYPositive Net Change ABBVPositive Net Change ANIPNegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
by Sundeep Ganoria
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change MDGLNegative Net Change
biotechs medical pharmaceuticals
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
GSKPositive Net Change ANIPNegative Net Change VYGRPositive Net Change
biotechs
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
by Zacks Equity Research
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
EXELNegative Net Change JAZZPositive Net Change NVAXPositive Net Change VNDANegative Net Change
biotechnology biotechs medical pharmaceuticals
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
by Zacks Equity Research
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
GSKPositive Net Change FOLDPositive Net Change WVEPositive Net Change KRROPositive Net Change
biotechnology biotechs medical pharmaceuticals
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
by Zacks Equity Research
ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR amyloidosis with cardiomyopathy.
ALNYPositive Net Change NVSPositive Net Change FOLDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
by Zacks Equity Research
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
by Zacks Equity Research
The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.
ALNYPositive Net Change ANIPNegative Net Change VYGRPositive Net Change IMRXPositive Net Change
biotechs
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
by Zacks Equity Research
MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.
ALNYPositive Net Change FOLDPositive Net Change ANIPNegative Net Change MGTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines